Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD Study of ACD856 in Healthy Volunteers
NCT05077501Phase 1Completed
- Sponsor
- AlzeCure Pharma
- Start
- Sep 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing ACD856 Arm with Placebo Arm (2 arms). Primary endpoints: Frequency of adverse events at 16 days, Clinically significant changes in 12-lead ECGs at 16 days and 7 more. Started Sep 2021; status: completed.
02
Drugs
ACD856
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05077501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077501.